Skip to content

Biomarkers of 4-hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) intake identified from human hepatocyte incubations

J. Carlier, S. Malaca, M. Huestis, A. Tagliabracci, Anastasio Tini, F. Busardò

Expert Opinion on Drug Metabolism & Toxicology December 2, 2022 DOI: 10.1080/17425255.2022.2166826 via Semantic Scholar

Summary

AI-generated from the abstract

The psychedelic tryptamine 4-hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) is metabolized by human hepatocytes into three phase I and four phase II metabolites, including N-oxidation and N-demethylation products as well as glucuronide and sulfate conjugates. These findings suggest that 4-OH-MPT-N-oxide and 4-hydroxy-N,N-propyltryptamine (4-OH-PT) can serve as biomarkers of intake after hydrolysis of glucuronide or sulfate conjugates in biological samples, while 4-OH-MPT-glucuronide is a useful biomarker when hydrolysis is not performed. The metabolic profile aligns with that of other tryptamine analogues, and further research is needed to confirm the specificity of these markers for forensic or clinical detection.

Study at a glance

Characteristics In vitro metabolic study Peer reviewed
Population 10-donor-pooled human hepatocytes
Keywords Medicine Chemistry
Key finding 4-OH-MPT is metabolized into three phase I and four phase II metabolites, with 4-OH-MPT-N-oxide and 4-OH-PT recommended as biomarkers after hydrolysis, and 4-OH-MPT-glucuronide as an alternative biomarker without hydrolysis.

Abstract

ABSTRACT Background 4-Hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) is a psychedelic tryptamine whose use is regulated in several countries. Due to unspecific effects, consumption can be ascertained only through toxicological analyses. However, the trace amounts of tryptamines are usually challenging to detect in biological samples. 4-OH-MPT metabolism was characterized to identify optimal metabolite markers of intake in clinical/forensic toxicology. Research design and methods 4-OH-MPT was incubated with 10-donor-pooled human hepatocytes to simulate in vivo conditions; samples were analyzed by liquid chromatography-high-resolution tandem mass spectrometry (LC-HRMS/MS), and data were processed with Compound Discoverer from Thermo Scientific. LC-HRMS/MS and data mining were supported by in silico metabolite predictions (GLORYx). Results Three phase I and four phase II metabolites were identified, including N-oxidation and N-demethylation at the alkylamine chain, and O-glucuronidation and sulfation at the hydroxylindole core. Conclusions 4-OH-MPT metabolic fate was consistent with the human metabolism of tryptamine analogues: we suggest 4-OH-MPT-N-oxide and 4-hydroxy-N,N-propyltryptamine (4-OH-PT) as metabolite biomarkers of 4-OH-MPT consumption after glucuronide/sulfate hydrolysis in biological samples to improve detection of 4-OH-MPT and phase I metabolites; 4-OH-MPT-glucuronide is suggested as an additional biomarker when hydrolysis is not performed. Further research on the metabolism of structural analogues is necessary to evaluate the specificity of 4-OH-MPT metabolite biomarkers.

Comments

No comments yet.

Log in to comment